|
Medication Errors
FDA receives medication error
reports on marketed human drugs (including prescription drugs, generic drugs,
and over-the-counter drugs) and nonvaccine biological products and devices.
The National Coordinating Council for Medication Error
Reporting and Prevention defines a medication error as "any preventable
event that may cause or lead to inappropriate medication use or patient harm while
the medication is in the control of the health care professional, patient, or consumer.
Such events may be related to professional practice, health care products, procedures,
and systems, including prescribing; order communication; product labeling, packaging,
and nomenclature; compounding; dispensing; distribution; administration; education;
monitoring; and use."
The American Hospital Association
lists the following as some common types of medication errors:
- incomplete patient information (not knowing about patients' allergies, other medicines
they are taking, previous diagnoses, and lab results, for example);
- unavailable drug information (such as lack of up-to-date warnings);
- miscommunication of drug orders, which can involve poor handwriting, confusion between
drugs with similar names, misuse of zeroes and decimal points, confusion
of metric and other dosing units, and
inappropriate abbreviations;
- lack of appropriate labeling as a drug is prepared and repackaged into smaller units;
and
- environmental factors, such as lighting, heat, noise, and interruptions, that can
distract health professionals from their medical tasks.
In 1992, the FDA began monitoring medication error reports that are forwarded to
FDA from the United States Pharmacopeia (USP)
and the Institute for Safe Medication Practices (ISMP).
The Agency also reviews MedWatch reports
for possible medication errors. Currently, medication errors are reported to the
FDA as manufacturer reports (adverse events resulting in serious injury and for
which a medication error may be a component), direct contact reports (MedWatch),
or reports from USP or ISMP.
The Division of Medication Errors and Technical Support includes a medication error
prevention program staffed with pharmacists and support personnel. Among their many
duties, program staff review medication error reports sent to the
USP-ISMP Medication Errors Reporting Program and MedWatch, evaluate causality,
and analyze the data to provide feedback to others at FDA.
Back to Top
Medication Safety Information from Drug Topics FDA
Safety Page
- Bextra: Valdecoxib or bucindolol?
- Curbing med errors involving Anzemet, Bentyl
- Confusion between methylphenidate and methadone
- Drug errors associated with opium tincture
and paregoric
- Drug errors involving Keppra and Kaletra
- Fatal medication errors associated with Temodar
- Kaopectate reformulation and upcoming label change
- Medication errors associated with serzone and seroquel
- Misadministration of capsules for inhalation (Foradil
and Spiriva)
- Transdermal patches: High risk for error?
Medication Errors Information from FDA
- Elan Pharmaceuticals issued a "Dear Healthcare Professional" October 6, 2003 reporting
serious adverse events and deaths resulting from accidental overdose of high concentration
morphine sulfate oral solutions.
MedWatch Safety Information (Posted 10/9/2003)
- Dispensing
errors associated with lamictal (lamotrigine) tablets
- FDA and UCB Pharma advised healthcare professionals of the risk of dispensing errors
between KEPPRA (levetiracetam), an antiepileptic, and KALETRA (lopinavir/ritonavir),
an antiretroviral.
MedWatch Safety Information (Posted 10/9/2003)
- FDA, Janssen Pharmaceutical Products, and Johnson & Johnson Pharmaceutical Research
& Development notify healthcare professionals of reports of medication errors
involving confusion between Reminyl and Amaryl (glimepiride).
MedWatch Safety Info. (Posted 10/26/2004)
- Medication errors associated with flomax and volmax
- Medication errors associated with zantac and zyrtec
Medication Safety Alerts from Institute for Safe Medication Practices
|
Back to Top
Campaign to Eliminate Use
of Error-Prone Abbreviations
FDA and the Institute for Safe Medication
Practices (ISMP) have launched a national education campaign to eliminate the use
of ambiguous medical abbreviations that are frequently misinterpreted and lead to
mistakes that result in patient harm. The campaign seeks to promote safe practices
among those who communicate medical information.
As part of the campaign, FDA recommends that healthcare professionals consider ISMP’s
List of Error-Prone Abbreviations, Symbols, and Dose Designations at
https://www.ismp.org/tools/errorproneabbreviations.pdf
[external link]
whenever medical information is communicated. In addition, FDA and ISMP have provided
a toolkit of resource materials available at
www.ismp.org/tools/abbreviations. [external link]
FDA News: FDA and ISMP Launch Campaign to Reduce Medication Mistakes Caused
by Unclear Medical Abbreviations.
Federal Regulations and Guidances
- FDA proposes
bar codes for drugs, blood; new adverse reaction reporting.
-
Guidance for Hospitals, Nursing
Homes, and Other Health Care Facilities - FDA Public Health Advisory.
(Issued and Posted 4/5/2001). This guidance is intended to alert hospitals,
nursing homes, and other health care facilities to the hazards of medical gas mix-ups.
-
Flyer on FDA Public Health Advisory:
Medical Gas Mix-Ups Can Cause Death and Serious Injury Optional
format: HTML (Posted 10/10/2001).
This one-page, color flier is intended to alert people who handle
medical gases about the hazards of mix-ups. Please feel free to
copy and distribute this flier. Comments and suggestions
are welcome.
-
FDA Proposed New Format for
Physician Prescription Drug Labeling.
FDA has proposed a new, user-friendly format for the labeling information doctors
get about prescription drugs. FDA believes that this new, user-
friendly format will reduce errors in drug prescribing.
-
Federal Food, Drug
and Cosmetic Act, as Amended, Section 502 (e).
-
Code of Federal Regulations 21 CFR 201.10 (c);
201.56(b); and
299.4.
Other Resources
Back to Top
Back to Drug Information
|
|